A family office with offices in the Northeast and Midwestern United Sates invests its principal capital into high growth companies, both privately held and publicly listed. The firm’s investment size is highly variable and dependent on the financial needs of the company. The firm often leads investment rounds and also has the ability to leverage its additional network of high-net-worth families and like-minded co investors to syndicate for larger deals as well as follow on investments.  The firm looks to invest in companies throughout the United States and has no set number of investments in plans to make, however they are actively reviewing new opportunities.

Within healthcare, the firm is most interested in companies developing Devices and Diagnostics. The firm is looking for companies devices that solve a significant medical problem with strong IP supporting it. The firm is willing to invest in companies from the prototype stage to those that already have their products on the market and is generally agnostic in terms of indication. Historically the firm has invested in companies working with cardiac devices and also has held special interest in the pediatrics space. The firm is generally not as interested in consumer facing devices. The firm is also willing to consider investments in the Therapeutics space though this area is less of a focus.

The firm is looking for companies that have experienced management teams and a strong board behind them. The firm is willing to invest in both privately and publicly held companies with a special interest in making PIPE investments. The firm looks to take a board seat into companies on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a hi-tech company currently manages a total of $850 million in assets, and is looking to make equity investments ranging from $2-$5 million with the ability to allocate up to $10 million generally in series A-C rounds. The majority of the fund’s investment has been throughout the United States though the fund has invested and is willing to invest internationally as well. The fund is actively reviewing new opportunities and can make 3-4 investments over the next year.

The fund is currently interested in sectors of Medical Devices, Diagnostics and Healthcare IT that increase connectivity in the healthcare ecosystem. The fund is particularly interest in verticals of Health and Wellness, Chronic Disease Care, Aging in Place, Telemedicine, Genomics, Patient Monitoring, Clinical Trails Management, Mobile Software Healthcare IT Applications, and Electronic Medical Records Management. The fund is willing to invest in devices with 510k pathways; however the fund is not currently considering highly invasive medical devices.

The fund is looking for privately held companies with experienced management teams. The fund generally looks to take a board or observer seat following investment and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Spanish independent venture capital firm is currently providing private equity financing to early- and mid-stage human healthcare and life science companies. The firm has € 118 million in assets under management distributed over two funds. The second fund has a target size of € 100 million and will remain open to new investors until September 2015. The firm can allocate up to €7M (in equity) per company, generally co-investing with other specialized investors. The firm looks for companies that are based in Europe and the US.

The firm targets the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices. The firm is opportunistic in terms of indications and seeks products that have an attractive market potential. In case of niche/orphan indications, the potential market share should be significant and realistic. For therapeutics, the firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have a solid animal data. For medical devices, the firm is also opportunistic and looks for devices that have a working prototype.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist investor that is funded by private capital was founded in 2011 and has operations in Luxembourg, Belgium and USA. The firm exclusively focuses on investments in early-stage drug development companies targeting cancer therapies. The firm is most interested in companies from late seed stage to series A. The investment size will vary, and it can range from a few hundred thousand dollars up to a couple of million dollars. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently looking for new investments targeting the development of oncology therapies. The firm will not invest in medical device or diagnostics. The firm typically invests in companies with solid preclinical proof of concept (late preclinical stage/ pre-IND), and it will fund the companies at least up to human proof of concept (clinical phase Ib/ phase IIa). The firm prefers to invest in companies with small pipeline and a clear regulatory pathway. Historically, the firm was active in companies targeting immune therapy and tumor cell metabolism within the oncology field.

The firm primarily invests in private companies with experienced management team and breakthrough potential. The firm looks to be a lead investor and may take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund financed entirely by a Russian pharmaceutical company is looking to make investments ranging from $5-$15 million in companies in the life science space. The firm could make as many as 2-3 investments over the next 6-9 months and is willing to allocate to companies around the globe. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The fund is currently looking for companies developing therapeutics and is open to both small molecules, biologics, and cell/gene therapy. The firm is more interested in companies working with single assets though they are also willing to consider platform technologies. Indications of interest include Oncology, Inflammation, Neurodegenerative diseases, Orphan genetic diseases, Critical care, Regenerative medicine and Cardiovascular. The firm looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The fund is looking for privately held companies and prefers companies with experienced management teams in place. The firm looks to act as a value-added investor through their strategic alignment with its parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. The company is most interested in neurology, hepatology, and gastroenterology. However, the firm is also interested in other therapeutic areas that address large unmet medical needs. The company will look at both small molecules and biologics and will consider only NCE or NCE-like molecules (such as repositioning molecule, new indication, etc). The company prefers assets in phase I, II, or IND-ready. However, the company will also look at assets in phase III and NDA stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com